Comparing the current results to its competitors, Immunome Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.39 %, recorded in the same quarter.
Immunome Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology sector, focusing on cancer therapies. Its commercial prospects may be affected if competitors develop products that are safer, more effective, more convenient, less expensive, or otherwise render its products obsolete. Competitors may also obtain marketing approvals more quickly, establishing market positions before the company can enter. The company competes with oncology firms developing small molecules, antibody-drug conjugates (ADCs), targeted radiotherapies, antibodies, and other therapies. Notable competitors include AbbVie Inc. (which acquired Immunogen), AstraZeneca, Amgen, and Bay.
May 20, 2024
BOTHELL, Wash. Immunome, Inc. (Nasdaq: IMNM), a biotech firm renowned for its pioneering work in developing targeted cancer therapies, has announced the successful acquisition of antibodies and related assets from Atreca, Inc. This move is poised to significantly enhance Immunome’s therapeutic pipeline and fortify its position in the oncology sector. Strategic Acquisition DetailsThe completed transaction involves an upfront payment of $5.5 million by Immunome to Atreca. Additionally, Atreca stands to receive up to $7.0 million contingent on achieving specified clinical development milestones. This strategic acquisition includes the transfer of rights to 28 unique antibodies, along with associated material...
March 18, 2024
In the pursuit of groundbreaking targeted cancer therapies, biotechnology company Immunome Inc. has chosen Arrayjet s ArrayPlex discovery platform to bolster its in-house high-throughput screening tools. Through this collaboration, Immunome aims to accelerate the discovery and development of first-in-class and best-in-class cancer therapies. Arrayjet, a leading provider of inkjet liquid-handling solutions, is making its proprietary multi-layer microarray platform available to Immunome and other screening customers through its CRO/CMO services.Expanding High-Throughput Screening Capabilities:Immunome s decision to utilize Arrayjet s ArrayPlex platform illustrates the increasing significance of high-throughput...
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Sources:
Immunome Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunome Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
